Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6I5G

X-ray structure of human soluble Epoxide Hydrolase C-terminal Domain (hsEH CTD)in complex with 15d-PGJ2

Summary for 6I5G
Entry DOI10.2210/pdb6i5g/pdb
DescriptorBifunctional epoxide hydrolase 2, 1,2-ETHANEDIOL, (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid, ... (4 entities in total)
Functional Keywordshseh ctd, apoprotein, alpha_beta hydrolase fold, 15d-pgj2, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight80468.19
Authors
Abis, G.,Kopec, J.,Yue, W.W.,Conte, M.R. (deposition date: 2018-11-13, release date: 2019-05-29, Last modification date: 2024-01-24)
Primary citationAbis, G.,Charles, R.L.,Kopec, J.,Yue, W.W.,Atkinson, R.A.,Bui, T.T.T.,Lynham, S.,Popova, S.,Sun, Y.B.,Fraternali, F.,Eaton, P.,Conte, M.R.
15-deoxy-Delta12,14-Prostaglandin J2inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
Commun Biol, 2:188-188, 2019
Cited by
PubMed Abstract: Human soluble epoxide hydrolase (hsEH) is an enzyme responsible for the inactivation of bioactive epoxy fatty acids, and its inhibition is emerging as a promising therapeutical strategy to target hypertension, cardiovascular disease, pain and insulin sensitivity. Here, we uncover the molecular bases of hsEH inhibition mediated by the endogenous 15-deoxy-Δ-Prostaglandin J (15d-PGJ). Our data reveal a dual inhibitory mechanism, whereby hsEH can be inhibited by reversible docking of 15d-PGJ in the catalytic pocket, as well as by covalent locking of the same compound onto cysteine residues C423 and C522, remote to the active site. Biophysical characterisations allied with in silico investigations indicate that the covalent modification of the reactive cysteines may be part of a hitherto undiscovered allosteric regulatory mechanism of the enzyme. This study provides insights into the molecular modes of inhibition of hsEH epoxy-hydrolytic activity and paves the way for the development of new allosteric inhibitors.
PubMed: 31123712
DOI: 10.1038/s42003-019-0426-2
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

236963

數據於2025-06-04公開中

PDB statisticsPDBj update infoContact PDBjnumon